Pharmaceutical Manufacturing of Dicyclomine Hydrochloride Tablets

The contract entails the full-scale manufacturing of Dicyclomine Hydrochloride Tablets, USP, covering all phases from formulation and tablet compression to comprehensive quality control testing, with strict adherence to current Good Manufacturing Practices. All production must meet U.S. Pharmacopeia standards and ensure consistent product quality, safety, and efficacy throughout the supply chain. The work is being solicited as a subcontract under the Department of Defense's Medical Supply Chain Pharm FSA, with performance required at a military postal address in FPO, 09514, indicating potential logistical constraints and military-specific delivery requirements. The solicitation was posted on July 15, 2026, with a firm response deadline of July 21, 2026, leaving a narrow window for qualified manufacturers to submit proposals. The North American Industry Classification System code 325412 identifies the activity as pharmaceutical preparation manufacturing, underscoring the technical and regulatory precision expected from the contractor. While no set-aside type or point of contact is specified, the contract's military context implies stringent compliance, documentation, and security protocols beyond typical commercial pharmaceutical manufacturing requirements, making experience in defense or government supply chain operations a critical advantage for bidders.